EP. 18 A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care
November 6th, 2026Talazoparib triplet joins treatment options for HRR-mutated mHSPCBiomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.Read more
November 4th, 2026Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamideAlicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.Read more
November 3rd, 2026Aaron Berger, MD, discusses considerations for ARPI treatment breaksAaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.Read more
November 2nd, 2026Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaPTamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.Read more
October 31st, 2026Comparing PSMA-PET agents: What urologists should knowChad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.Read more
October 30th, 2026Chad Ritch, MD, on using PSMA-PET to guide treatment decisionsChad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.Read more
October 30th, 2026Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,Read more
October 28th, 2026CLARIFY trial reaches enrollment target for 64Cu-SAR-bisPSMA in prostate cancerTopline results from the study are anticipated in the first half of 2027.Read more